Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jun 25, 2026
Why Is H.B. Fuller Company (FUL) Stock Down -6.38% Today?

Why Is H.B. Fuller Company (FUL) Stock Down -6.38% Today?

Key Takeaways

  • FUL shares declined approximately 6.38% in premarket trading on June 25, 2026, falling to around $60.45 from the prior session's close of $62.75
  • The primary catalyst was H.B. Fuller's formal confirmation of a £715 million (~$942M) all-cash acquisition of Advanced Medical Solutions Group (AMS), a UK-based medical wound-care company
  • A secondary driver was the company's fiscal Q2 earnings report, which — despite beating revenue estimates — delivered a guidance midpoint slightly below analyst consensus, disappointing investors who had priced in a more aggressive outlook
  • Activist investor Ancora Holdings, which owns over 2% of FUL shares, had publicly opposed the AMS deal since May, warning of dangerous leverage escalation above 4.0x Net Debt/EBITDA and raising concerns about management's ability to execute a complex cross-border acquisition
  • The selloff unfolded against a cautious broader market backdrop, with the S&P 500 and Nasdaq both edging lower
  • Traders are watching whether Ancora escalates its opposition to a proxy fight and how credit rating agencies respond to the jump in leverage

Opening Summary

H.B. Fuller Company (FUL), traded on the NYSE, is one of the world's largest standalone specialty adhesives manufacturers, providing bonding, sealing, and coating solutions across construction, electronics, packaging, and industrial markets. Shares dropped approximately 6.38% in Thursday premarket trading, falling from a prior close of $62.75 to roughly $60.45, after the company simultaneously released a mixed quarterly earnings report and formally announced a contested $942 million acquisition. The twin announcements — neither of which fully satisfied market expectations — combined to erase gains built up over the prior several weeks.

The AMS Acquisition: A Deal Market Didn't Want

The dominant driver behind FUL's premarket selloff was the formal announcement of an all-cash offer to acquire Advanced Medical Solutions Group plc (AMS), a UK-listed wound-care and medical adhesives company, at £2.85 per share — representing a 35% premium over AMS's pre-offer closing price and a total enterprise valuation of £715 million (~$942 million including debt). H.B. Fuller argued the deal would grow its total addressable market from $80 billion to $95 billion and generate approximately $55 million in combined revenue and cost synergies by 2031. The AMS board unanimously recommended the offer to its shareholders, and the transaction is expected to close by year-end 2026.

However, investors reacted negatively to the capital allocation decision. Analysts flagged that the fully debt-funded deal is projected to push FUL's leverage above 4.0x Net Debt/Proforma Adjusted EBITDA — a threshold the company's own management had previously pledged to stay below. The AMS transaction moves FUL into unfamiliar medical-device territory with complex European regulatory frameworks, raising integration execution risk.

Activist Opposition Amplifies Selling Pressure

The acquisition announcement confirmed the fears that activist investor Ancora Holdings had been publicly voicing since May 2026. Ancora, with a greater than 2% stake in FUL, had sent sharply worded letters to the board calling the pursuit of AMS "an extremely risky, quasi-transformational international acquisition completely out of management's depth," and warned it would pursue a proxy fight if the deal proceeded. Ancora's concern was that the deal contradicted H.B. Fuller's prior commitments to prioritize debt reduction and share buybacks, noting that the company had repurchased 750,000 shares in Q2 alone while simultaneously moving forward on a leverage-heavy strategic acquisition. With the deal now formally confirmed, the activist's objections transformed from speculative risk into a live corporate governance overhang.

Q2 Earnings: A Beat That Wasn't Enough

On the evening of June 24, FUL reported fiscal Q2 results for the quarter ended May 30, 2026, that technically beat estimates on both lines. Revenue reached $950.3 million, up 5.8% year-over-year and ahead of the $923.67 million consensus, while adjusted EPS came in at $1.41, above the $1.38 estimate. Adjusted EBITDA rose 9% year-over-year to $181 million, and the company generated a record Q2 operating cash flow of $121 million. Despite the beat, the full-year adjusted EPS guidance range of $4.60–$4.90 — with a midpoint of $4.75 — landed just below the analyst consensus of $4.77, signaling to investors that management was not raising the bar aggressively enough given the recent stock run-up of more than 9% over the prior month.

Market Context and Trading Activity

The premarket decline in FUL shares stood out against a broadly flat-to-slightly-lower equity market, with the S&P 500 edging down approximately 0.1% and the Nasdaq declining roughly 0.4% — confirming the move was stock-specific rather than macro-driven. Volume in the premarket session was notably elevated relative to typical pre-open activity, consistent with a dual catalyst event involving both an earnings release and a material M&A announcement. The stock had been trading up over 7% year-to-date ahead of Thursday's session, with a particularly strong run in the prior 30 days, meaning investor expectations were elevated and the bar for positive surprise was correspondingly high. The combination of barely-in-line guidance and a leveraged acquisition created the conditions for an outsized price correction.

Trending AI Robots

For traders actively monitoring names like FUL during volatile, news-driven sessions, Tickeron's Trending AI Robots page offers a curated selection of its highest-performing AI trading bots under current market conditions. Tickeron runs hundreds of AI-powered bots covering thousands of tickers, spanning a wide range of strategies — from momentum and swing trading to mean reversion — across various timeframes and asset classes. Only bots demonstrating the strongest recent performance metrics make the Trending list, giving traders a data-driven starting point. Each bot is transparent about its traded symbols, historical accuracy, and risk profile. Investors and active traders looking for systematic, AI-assisted approaches to navigating volatile markets may find the Trending AI Robots section a useful resource worth exploring.

What Comes Next for FUL

The most immediate watchpoint for FUL is the evolution of the Ancora situation — whether the activist firm formally escalates toward a proxy contest or seeks board representation in response to the AMS deal confirmation. On the corporate calendar, integration planning details and financing disclosures related to the AMS transaction will be closely watched, particularly how management addresses the projected leverage spike above 4.0x. Credit rating agency commentary could also become a near-term catalyst; any negative rating action tied to the balance sheet expansion may intensify selling pressure. Looking further ahead, FUL's fiscal Q3 earnings — which will be the first report to reflect management's post-deal capital allocation priorities — will be a critical test of whether the company can sustain its margin and cash flow trajectory while absorbing the costs of a large cross-border transaction. Risks include potential delays in the AMS deal closing timeline, continued activist opposition, currency exposure from the sterling-denominated transaction, and the broader macro environment's impact on adhesives demand across construction and industrial end markets.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: FUL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


FUL sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for FUL moved below the 200-day moving average on July 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for FUL moved out of overbought territory on August 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FUL as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FUL turned negative on August 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

FUL moved below its 50-day moving average on August 20, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FUL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FUL broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for FUL entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for FUL crossed bullishly above the 50-day moving average on August 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FUL advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.516) is normal, around the industry mean (7.001). P/E Ratio (17.418) is within average values for comparable stocks, (39.393). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.393). Dividend Yield (0.016) settles around the average of (0.019) among similar stocks. P/S Ratio (0.925) is also within normal values, averaging (70.976).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FUL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FUL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 12.06B. The market cap for tickers in the group ranges from 47 to 224.76B. LIN holds the highest valuation in this group at 224.76B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was -1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 6%. CITR experienced the highest price growth at 21%, while LWLG experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was 25%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 58
Price Growth Rating: 51
SMR Rating: 77
Profit Risk Rating: 81
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
FUL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of adhesives, sealants and other chemical products

Industry ChemicalsSpecialty

Profile
Details
Industry
Industrial Specialties
Address
1200 Willow Lake Boulevard
Phone
+1 651 236-5900
Employees
7200
Web
https://www.hbfuller.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.